ATE340165T1 - Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben - Google Patents
Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften habenInfo
- Publication number
- ATE340165T1 ATE340165T1 AT02703421T AT02703421T ATE340165T1 AT E340165 T1 ATE340165 T1 AT E340165T1 AT 02703421 T AT02703421 T AT 02703421T AT 02703421 T AT02703421 T AT 02703421T AT E340165 T1 ATE340165 T1 AT E340165T1
- Authority
- AT
- Austria
- Prior art keywords
- molecules
- relates
- present
- combi
- signal transmission
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000008054 signal transmission Effects 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 238000007429 general method Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27086801P | 2001-02-26 | 2001-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE340165T1 true ATE340165T1 (de) | 2006-10-15 |
Family
ID=23033147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02703421T ATE340165T1 (de) | 2001-02-26 | 2002-02-26 | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7572798B2 (de) |
| EP (1) | EP1366027B1 (de) |
| AT (1) | ATE340165T1 (de) |
| CA (1) | CA2439143A1 (de) |
| DE (1) | DE60214828T2 (de) |
| WO (1) | WO2002068396A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| AU2007296740B2 (en) | 2006-09-11 | 2012-09-27 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| CN101534831B (zh) | 2006-09-11 | 2013-07-17 | 柯瑞斯公司 | 包含锌结合基团的取代的酪氨酸抑制剂 |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP5580592B2 (ja) | 2006-09-11 | 2014-08-27 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| ES2526718T3 (es) | 2007-09-10 | 2015-01-14 | Curis, Inc. | Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| CN101619043B (zh) * | 2008-06-30 | 2013-06-05 | 和记黄埔医药（上海）有限公司 | 喹唑啉衍生物及其医药用途 |
| CN102485735B (zh) * | 2010-12-02 | 2014-09-24 | 东莞南方医大代谢医学研发有限公司 | 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途 |
| CN119019408B (zh) * | 2024-08-15 | 2025-02-28 | 中山大学附属第三医院 | Egfr-mek-tz三联合分子ln-1及其制备方法和用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
-
2002
- 2002-02-26 AT AT02703421T patent/ATE340165T1/de not_active IP Right Cessation
- 2002-02-26 CA CA002439143A patent/CA2439143A1/en not_active Abandoned
- 2002-02-26 WO PCT/CA2002/000253 patent/WO2002068396A1/en not_active Ceased
- 2002-02-26 EP EP02703421A patent/EP1366027B1/de not_active Expired - Lifetime
- 2002-02-26 US US10/469,368 patent/US7572798B2/en not_active Expired - Fee Related
- 2002-02-26 DE DE60214828T patent/DE60214828T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60214828T2 (de) | 2007-09-06 |
| US7572798B2 (en) | 2009-08-11 |
| EP1366027B1 (de) | 2006-09-20 |
| US20040086907A1 (en) | 2004-05-06 |
| WO2002068396A1 (en) | 2002-09-06 |
| CA2439143A1 (en) | 2002-09-06 |
| EP1366027A1 (de) | 2003-12-03 |
| DE60214828D1 (de) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE532860T1 (de) | B7-ähnliche moleküle und deren anwendungen | |
| NL300933I2 (nl) | Letermovir | |
| ATE340165T1 (de) | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben | |
| DE60204722D1 (de) | Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten | |
| ATE167680T1 (de) | Pteridin-nukleotidderivate als fluoreszierende sonden | |
| ATE376835T1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
| DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| ATE313532T1 (de) | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen | |
| DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
| WO2003005999A3 (en) | Methods of treating cytokine mediated diseases | |
| PL365637A1 (en) | Quinazoline ditosylate salt compounds | |
| BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
| WO2003049702A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| ITBO20020620A1 (it) | Condotto multi-canale bioriassorbibile di rigenerazione del nervo e processo per preparare il medesimo. | |
| CA2533963A1 (en) | Urea derivatives and the use thereof as inhibitors of tyrosine kinases | |
| EP1350763A4 (de) | Sapo-11 molekularsieb : sein syntheseverfahren und katalysator das molekularsieb enthaltend | |
| DE60318839D1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
| DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| WO2003082268A3 (en) | Hemiasterlin derivatives and uses thereof in the treatment of cancer | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| WO2001072685A3 (en) | Polyamine analogues as cytotoxic agents | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| EP1573023A4 (de) | Nukleinsäure und dieser entsprechendes, 162p1e6 genanntes, für die behandlung und den nachweis von krebs geeignetes protein | |
| MXPA03010728A (es) | Moleculas de proteina-2 relacionadas con b7 y uso de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |